0 171

Cited 270 times in

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

DC FieldValueLanguage
dc.contributor.author조병철-
dc.date.accessioned2019-09-20T07:41:39Z-
dc.date.available2019-09-20T07:41:39Z-
dc.date.issued2019-
dc.identifier.issn0140-6736-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/171016-
dc.description.abstractBACKGROUND: First-line pembrolizumab monotherapy improves overall and progression-free survival in patients with untreated metastatic non-small-cell lung cancer with a programmed death ligand 1 (PD-L1) tumour proportion score (TPS) of 50% or greater. We investigated overall survival after treatment with pembrolizumab monotherapy in patients with a PD-L1 TPS of 1% or greater. METHODS: This randomised, open-label, phase 3 study was done in 213 medical centres in 32 countries. Eligible patients were adults (≥18 years) with previously untreated locally advanced or metastatic non-small-cell lung cancer without a sensitising EGFR mutation or ALK translocation and with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, life expectancy 3 months or longer, and a PD-L1 TPS of 1% or greater. Randomisation was computer generated, accessed via an interactive voice-response and integrated web-response system, and stratified by region of enrolment (east Asia vs rest of world), ECOG performance status score (0 vs 1), histology (squamous vs non-squamous), and PD-L1 TPS (≥50% vs 1-49%). Enrolled patients were randomly assigned 1:1 in blocks of four per stratum to receive pembrolizumab 200 mg every 3 weeks for up to 35 cycles or the investigator's choice of platinum-based chemotherapy for four to six cycles. Primary endpoints were overall survival in patients with a TPS of 50% or greater, 20% or greater, and 1% or greater (one-sided significance thresholds, p=0·0122, p=0·0120, and p=0·0124, respectively) in the intention-to-treat population, assessed sequentially if the previous findings were significant. This study is registered at ClinicalTrials.gov, number NCT02220894. FINDINGS: From Dec 19, 2014, to March 6, 2017, 1274 patients (902 men, 372 women, median age 63 years [IQR 57-69]) with a PD-L1 TPS of 1% or greater were allocated to pembrolizumab (n=637) or chemotherapy (n=637) and included in the intention-to-treat population. 599 (47%) had a TPS of 50% or greater and 818 patients (64%) had a TPS of 20% or greater. As of Feb 26, 2018, median follow-up was 12·8 months. Overall survival was significantly longer in the pembrolizumab group than in the chemotherapy group in all three TPS populations (≥50% hazard ratio 0·69, 95% CI 0·56-0·85, p=0·0003; ≥20% 0·77, 0·64-0·92, p=0·0020, and ≥1% 0·81, 0·71-0·93, p=0·0018). The median surival values by TPS population were 20·0 months (95% CI 15·4-24·9) for pembrolizumab versus 12·2 months (10·4-14·2) for chemotherapy, 17·7 months (15·3-22·1) versus 13·0 months (11·6-15·3), and 16·7 months (13·9-19·7) versus 12·1 months (11·3-13·3), respectively. Treatment-related adverse events of grade 3 or worse occurred in 113 (18%) of 636 treated patients in the pembrolizumab group and in 252 (41%) of 615 in the chemotherapy group and led to death in 13 (2%) and 14 (2%) patients, respectively. INTERPRETATION: The benefit-to-risk profile suggests that pembrolizumab monotherapy can be extended as first-line therapy to patients with locally advanced or metastatic non-small-cell lung cancer without sensitising EGFR or ALK alterations and with low PD-L1 TPS. FUNDING: Merck Sharp & Dohme.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherElsevier-
dc.relation.isPartOfLancet-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAged-
dc.subject.MESHAnaplastic Lymphoma Kinase/drug effects-
dc.subject.MESHAnaplastic Lymphoma Kinase/genetics-
dc.subject.MESHAntibodies, Monoclonal, Humanized/administration & dosage-
dc.subject.MESHAntibodies, Monoclonal, Humanized/adverse effects*-
dc.subject.MESHAntibodies, Monoclonal, Humanized/therapeutic use-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/administration & dosage-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/adverse effects-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use-
dc.subject.MESHB7-H1 Antigen/metabolism*-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/drug therapy*-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/metabolism-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/pathology-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/secondary*-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHDrug Administration Schedule-
dc.subject.MESHFar East/epidemiology-
dc.subject.MESHFemale-
dc.subject.MESHGenes, erbB-1/drug effects-
dc.subject.MESHGenes, erbB-1/genetics-
dc.subject.MESHHumans-
dc.subject.MESHLung Neoplasms/drug therapy*-
dc.subject.MESHLung Neoplasms/metabolism-
dc.subject.MESHLung Neoplasms/pathology-
dc.subject.MESHLung Neoplasms/secondary-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHMutation-
dc.subject.MESHNeoplasm Metastasis/pathology-
dc.subject.MESHTranslocation, Genetic-
dc.titlePembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorTony S K Mok-
dc.contributor.googleauthorYi-Long Wu-
dc.contributor.googleauthorIveta Kudaba-
dc.contributor.googleauthorDariusz M Kowalski-
dc.contributor.googleauthorByoung Chul Cho-
dc.contributor.googleauthorHande Z Turna-
dc.contributor.googleauthorGilberto Castro-
dc.contributor.googleauthorVichien Srimuninnimit-
dc.contributor.googleauthorKonstantin K Laktionov-
dc.contributor.googleauthorIgor Bondarenko-
dc.contributor.googleauthorKaoru Kubota-
dc.contributor.googleauthorGregory M Lubiniecki-
dc.contributor.googleauthorJin Zhang-
dc.contributor.googleauthorDebra Kush-
dc.contributor.googleauthorGilberto Lopes-
dc.identifier.doi10.1016/S0140-6736(18)32409-7-
dc.contributor.localIdA03822-
dc.relation.journalcodeJ02152-
dc.identifier.eissn1474-547X-
dc.identifier.pmid30955977-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0140673618324097-
dc.contributor.alternativeNameCho, Byoung Chul-
dc.contributor.affiliatedAuthor조병철-
dc.citation.volume393-
dc.citation.number10183-
dc.citation.startPage1819-
dc.citation.endPage1830-
dc.identifier.bibliographicCitationLancet, Vol.393(10183) : 1819-1830, 2019-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.